Format

Send to

Choose Destination
Peptides. 2019 Apr;114:29-37. doi: 10.1016/j.peptides.2019.04.005. Epub 2019 Apr 5.

Elabela protects against podocyte injury in mice with streptozocin-induced diabetes by associating with the PI3K/Akt/mTOR pathway.

Author information

1
Department of Nephrology, Second Hospital of Jilin University, Changchun 130041, China.
2
Department of Nephrology, Second Hospital of Jilin University, Changchun 130041, China. Electronic address: wenpengcui@163.com.
3
Department of Nephrology, Second Hospital of Jilin University, Changchun 130041, China. Electronic address: miaolining66@126.com.

Abstract

Diabetic nephropathy is a common complication of diabetes characterized by an increased rate of protein excretion in urine and kidney function loss. Elabela is a newly discovered peptide whose role in the regulation of diabetes is the major focus of this research. We established an in vivo model of Type 1 diabetes mellitus by injecting mice intraperitoneally with streptozotocin. The treatment group was administered Elabela for 6 months. In the present study, Elabela administration under diabetic conditions was found to reduce renal inflammation and fibrosis markers, leading to improvement in renal pathology and kidney dysfunction. Furthermore, Elabela acts through the phosphoinositide 3-kinase /Akt/mammalian target of rapamycin signaling pathway and decreases podocyte apoptosis, thereby exhibiting a nephroprotective effect against diabetic nephropathy. Our findings provide the first evidence that Elabela has a potential renoprotective effect in patients of diabetes.

KEYWORDS:

Apoptosis; Diabetes; Elabela; Kidney; PI3K/Akt/mTOR pathway; Podocyte

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center